$5 Million Common Stock Offering for Endonovo Therapeutics Designed to Advance SofPulse® Process for Medical Reimbursement
11. April 2022 09:08 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, April 11, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced significant advancement in the of process to obtain medical reimbursements for its...
Endonovo Therapeutics Announces Significant Results From Study Showing 70% Reduction of Morphine Equivalent Dose and 2 Day Reduction of Length of Stay at Hospitals Using SofPulse®
27. Juli 2020 09:00 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, July 27, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced that an investigator initiated study, authored by Dr. Samir...
Endonovo Therapeutics Announces Issuance of U.S. Patent Covering Apparatus and Method for Electromagnetic Treatment of Neurological Injury or Condition Caused by a Stroke
07. Januar 2020 08:30 ET
|
Endonovo Therapeutics, Inc.
Issuance of U.S. Patent No. 15217855 Further Bolsters Endonovo’s Intellectual Patent Portfolio Los Angeles, CA, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDVD /...
Endonovo Therapeutics Provides SofPulse® To All NFL Teams [Updated]
23. Dezember 2019 09:48 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDVD) ("Endonovo" or the "Company"), announced today the delivery of SofPulse® evaluation units to all...
Endonovo Therapeutics Provides SofPulse® To All NFL Teams
23. Dezember 2019 08:30 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today the delivery of SofPulse® evaluation units to all...
Endonovo Therapeutics Appoints Dr. Geoffrey Abrams of Stanford University to Its Scientific Advisory Board
30. August 2019 09:00 ET
|
Endonovo Therapeutics Inc.
LOS ANGELES, Aug. 30, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Endonovo Therapeutics Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of noninvasive Electroceutical®...
Endonovo Therapeutics Appoints Dr. Roc Alan McCarthy as a Scientific Advisory Board Member
09. Mai 2019 09:20 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA , May 09, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), today announced, that Roc Alan McCarthy, D.O. will be joining the company as a Scientific Advisory Board...
Endonovo Therapeutics Announces Steven Ford as V.P. Marketing
07. Mai 2019 09:20 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, May 07, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), today announced, Steven Ford will be joining the company as Vice President of Marketing. In his position,...
Endonovo Therapeutics Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office
18. Dezember 2018 09:25 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, CA, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapies...
Endonovo Expands SofPulse Commercialization
13. Dezember 2018 09:20 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, CA, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapies,...